• 1.

    Ruggenenti P, et al.. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:19411951.

  • 2.

    Yusuf S, et al.. Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145153.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    de Zeeuw D, et al.. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease for the BEACON trial investigators. N Engl J Med 2013; 369:24922503.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Menne J, et al.. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant 2017; 32:307315.

    • Search Google Scholar
    • Export Citation
  • 5.

    Wanner C, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323334.

  • 6.

    Zinman B, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:21172128.

  • 7.

    Perkovic V, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [published online ahead of print Apr 14, 2019]. N Engl J Med doi:10.1056/NEJMoa1811744.

    • Search Google Scholar
    • Export Citation
  • 8.

    Groop P-H, et al.. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial. Diabetes, Obes Metab 2017; 19:16101619.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Mann JFE, et al.. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839848.

  • 10.

    Van JAD, et al.. Insights into diabetic kidney disease using urinary proteomics and bioinformatics. J Am Soc Nephrol 2017; 28:10501061.

  • 11.

    Darshi M, et al.. Metabolomics in diabetic kidney disease: Unraveling the biochemistry of a silent killer. Am J Nephrol 2016; 44:92103.

  • 12.

    Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. Diabetologia 2018; 61:21082117.

    • Crossref
    • Search Google Scholar
    • Export Citation

Diabetic Kidney Disease What We Knew, What We Know, and What We Still Do Not Know

  • 1 Lidia Anguiano, PhD, and Hans-Joachim Anders, MD, are in the renal division of the Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Germany.
Restricted access
Save